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Working Toward a Frailty
Index in Transcatheter
Aortic Valve Replacement
A Major Move Away From the “Eyeball Test”*
Josep Rodés-Cabau, MD, Michael Mok, MBBS
Quebec City, Quebec, Canada
Transcatheter aortic valve replacement (TAVR) has become
an alternative treatment option for patients with severe
symptomatic aortic stenosis considered to be at high or
prohibitive surgical risk (1). However, despite TAVR being
associated with a very high procedural success rate (95%),
associated mortality rates at 1- and 2-year follow-up remain
15% and 30%, respectively (1–3). Central to the success
of any medical treatment is performance of the correct
procedure on the correct patient. Cardiac surgical risk scores
and subjective clinical impression have in general guided the
patient selection process and risk prediction in TAVR.
Cardiac risk scores, however, do not take into account some
important factors such as frailty, likely to be prevalent
among elderly persons and high-risk profile patients under-
going TAVR. The awareness of the concept of frailty in
cardiology and cardiac surgery parallels its increasing aware-
ness in fields of medicine outside gerontology (4,5) and now
has extended to TAVR. Frailty assessment of TAVR
candidates to date has been mainly based on the traditional
“eyeball” test, which is limited by its empirical nature,
leading to major personal biases, low reproducibility among
physicians and centers, and a lack of a scientifically proven
methodology.
See page 974
Frailty syndrome might be best described as a multi-
dimensional series of limitations characterized by dimin-
ished reserves and incapacity to adequately tolerate stressors.
However, as simplistic as the word “frailty” might seem,
there is neither a currently universally accepted definition of
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ontents of this paper to disclose.frailty nor a consensus about specific clinical measures or
laboratory markers for its diagnosis (6). Furthermore, ex-
tensive overlap and interactions occur in a nonlinear fashion
between disability, comorbidity, and frailty. The most com-
monly used definition of frailty is based on the criteria of
Fried et al. (7), which assess up to 5 domains—nutritional
status (weight loss), energy (exhaustion), physical activity
(leisure time activity), mobility (gait speed), and strength
(grip strength)—to define a frail phenotype and identify
older people at high risk for adverse outcomes. What is
agreed upon is the need to assess, in addition to physical
status, other domains such as cognitive ability, mood, and
mental health to obtain a more complete assessment of
frailty (6).
Although some studies provided some preliminary data
on the importance of the functional impairment pre-TAVR
as evaluated by the Karnofsky index (8) and the Duke
Activity Score index (9), Stortecky et al. (10) were the first
to use a multidimensional geriatric assessment for TAVR
candidates and found it to be associated with all-cause
mortality and major cardiovascular events at 30 days and at
1-year follow-up. This group also proposed a frailty index
from predetermined summary scores of instruments that
assessed pre-procedural nutritional, cognition, mobility, and
activities of daily living (ADL). In the same direction, in
this issue of JACC: Cardiovascular Interventions, Green et al.
(11) assessed frailty in 159 patients who received TAVR as
part of the PARTNER (Placement of AoRTic TraNscathetER
Valve Trial). The authors aimed to use some measures of
the original components of criteria of Fried et al. for frailty
(7). At an undefined time before TAVR, 4 factors were
measured: pre-procedural gait speed with a 15-ft timed walk
test, weakness by dominant hand-grip strength test, decline
in independence in ADL as evaluated by the Katz Index of
Independence in ADL survey, and measured serum albumin
as a surrogate for malnutrition and wasting. Domains as
defined by Fried et al. (7) that were not measured in this
study were: weight loss of 10 lbs or more in 1 year,
self-reported exhaustion, and decline in physical activity of 15
tasks of daily life. Green et al. divided the results of their 4
markers into quartiles and assigned scores (0 to 3) to each
quartile, thus deriving a frailty score, where highest (maximum
score  12) represented the most frail and lowest score
represented the least frail in their cohort. Those patients with
a score 5 had—dichotomizing the median-derived frailty
core—a higher 1-year mortality (hazard ratio: 3.5, 95%
onfidence interval: 1.4 to 8.5, p  0.007) after TAVR. In
act, after the periprocedural period (30 days), the mor-
ality rate at 1-year follow-up was as low as 3% among
atients with low frailty scores, as compared with 13%
mong patients with high frailty scores. The authors also
erived a simple comorbidity score in an attempt to corre-
ate frailty and comorbidity, finding no association between
omorbidities or Society of Thoracic Surgeons (STS) score
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983and frailty in TAVR patients. In addition when serum
albumin was analyzed in quartiles, it was found to correlate
with increased mortality in this high-risk cohort. However,
it is unclear as to the significance of this serum marker,
because hypoalbuminemia could also reflect the presence of
liver synthetic impairment, nephrotic syndrome, or mal-
absorption rather than a specific marker for malnutrition
and caloric wasting.
The most important message coming from this study is
that a simple and objective evaluation of the frailty status can
provide important prognostic information for TAVR candi-
dates. In addition, the prognostic value of a frailty index was
independent of other important comorbidities and the STS
score. Interestingly, a more advanced age and lower body mass
index, commonly used in the subjective “eyeball” evaluation of
frailty, were not associated with a higher frailty score, high-
lighting once again the importance of using objective tools for
the evaluation of this complex syndrome.
Although the work of Green et al. (11) represents an
important step forward in the assessment of frailty and in
the global evaluation of TAVR patients, there are many
unresolved issues. Although the prognostic value of a
multi-item assessment tool of frailty would probably surpass
that of a single-item assessment, the usefulness of each
individual component of the frailty score in predicting
outcomes after TAVR merits further evaluation in a larger
series of patients. Establishing TAVR-specific cutoffs for
each individual measure of frailty, which will ultimately
contribute to a TAVR frailty index, would probably provide
a better estimate of acute and late outcomes. Also, much
data exist on the prognostic value of several comorbidities
and procedural complications in patients undergoing TAVR
(1). However, no information was provided by the authors
on the selection criteria for the comorbidity factors used in
their comorbidity score, and further analyses using validated
comorbidity indexes are needed to confirm the lack of
significant interaction between frailty and other comorbidi-
ties in TAVR candidates. Also, it would be important to
determine whether or not similar frailty index cutoffs can be
applied in transfemoral versus other routes of access, espe-
cially those requiring a thoracotomy (transapical, transaor-
tic). The inclusion of domains such as cognitive status,
mood, or other aspects of mental health would probably
have high clinical relevance in the evaluation of frailty
pre-TAVR. Finally, improvements in health status and
quality of life after TAVR might be even more important
than improvements in longevity. Although TAVR has been
usually associated with marked improvements in functional
status and quality of life, a significant proportion of patients
experience mild or no improvement within the months after
the procedure (9,12). The potential impact of frailty on the
lack of significant functional status increase and quality-of-
life improvement after TAVR is an important point that
will also need to be addressed in future studies. vThe frailty syndrome is becoming a major factor in the
evaluation of cardiac patients, due to the increasing age of
the population. This is particularly true in the cohort of
patients with aortic stenosis considered to be at high or
prohibitive surgical risk undergoing TAVR. The work of
Green et al. (11) represents one of the first and a very
important step in the right direction toward establishing
objective tools for the evaluation of the frailty syndrome in
the setting of TAVR. The prospective validation of frailty
scores for the prediction of outcomes (survival and quality of
life) after TAVR might assist in determining the patients who
might or might not benefit from this procedure. Ultimately,
the incorporation of the frailty status into algorithms for
clinical decision making among TAVR candidates would be a
much-needed step toward providing the best care for this
complex and vulnerable group of patients.
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